Moreover, the suggested research focus may identify in Cav1 a promising novel target for therapeutic intervention—not only in FFA management, but also for other forms of cicatricial alopecia [94], as well as for other stem cell- and IP-related diseases such as multiple sclerosis [95] and autoimmune uveitis [96,97] and diseases characterized by pathological EMT like scleroderma [98]. This evidence concerns the gene CAV1 and cicatricial alopecia.